Fig. 5: The triple combination has increased DNA damage marker γ-H2A.X with reduced Mcl-1 and repressed p-Chk1. | Cell Death & Disease

Fig. 5: The triple combination has increased DNA damage marker γ-H2A.X with reduced Mcl-1 and repressed p-Chk1.

From: Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis

Fig. 5: The triple combination has increased DNA damage marker γ-H2A.X with reduced Mcl-1 and repressed p-Chk1.The alternative text for this image may have been generated using AI.

A THP-1 cells and MOLM-13 cells were treated as indicated and the protein levels were determined by Western blotting. B THP-1 cells were treated with 0.8 μM artesunate, 0.1 μM venetoclax, and 8 μM cytarabine at dual and triple combinations and MOLM-13 cells were treated with 0.2 μM artesunate, 0.01 μM venetoclax, and 0.08 μM cytarabine dual and triple combinations at the indicated times. Western blotting was performed to test protein changes. C THP-1 and MOLM-13 cells were pretreated with 25 μM Q-VD-OPh for 4 h, following by the dual and triple combinations. Western blotting was performed to test protein changes. D The DNA distribution assessed by flow cytometry after PI staining. The column graphs are the mean ± SD of three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001 compared to the control group by t-test. #P < 0.05; ##P < 0.01; ###P < 0.001 by two-way ANOVA test.

Back to article page